DXCM DexCom Inc
Company Analysis
Latest News
🟢 DexCom is trading 10% up today after beating Q2 estimates and raising full-year guidance
DexCom is trading 10% up at $82.00 after beating second-quarter 2026 estimates and raising its full-year revenue and margin guidance. • The company reported...
🟢 DexCom is trading 5.3% up today after Q2 beat and raised FY26 guidance
DexCom is trading at $78.51 (+5.33%) after reporting a strong second quarter and lifting full-year 2026 guidance. • Q2 revenue rose 13% to $1.308 billion with...
Dexcom beats second quarter estimates with 13% revenue growth and raises FY26 guidance.
DexCom reported second quarter 2026 revenue of $1.308 billion, up 13% year-over-year, and GAAP EPS of $0.64. The results prompted the company to raise its...
DexCom Inc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
DexCom is expected to report Q2 2026 revenue of $1.30 billion (+12% YoY) and EPS of $0.61 (+27.1% YoY), while the current stock price of $75.49 remains below...
Dexcom joins FDA TEMPO pilot, fast-tracking new tech and reimbursement
Dexcom has been selected as the inaugural participant in the FDA’s new TEMPO Digital Health Devices Pilot Program. This regulatory framework allows...
🔴 DexCom is trading 5.2% down
DexCom is trading at $70.83, down 5.2% from a comparison close of $74.75 during regular trading. This is a price-action follow-up, so a separate catalyst may...
🟢 DexCom is trading 4.8% up today despite sector-wide weakness
DexCom is trading 4.8% up at $76.30 today, showing significant strength despite a lack of company-specific catalysts. • The move appears to be driven by...
🔴 DexCom is trading 4% down today as healthcare stocks sell off following HCA Healthcare’s profit warning
DexCom is trading 4% down at $73.28 as a recent rebound stalled and healthcare stocks sell off following HCA Healthcare’s profit warning. • The move follows a...
🔴 DXCM is trading 4.2% down today amid sensor recall concerns and broader market risk-off tone
DXCM is trading at $70.47 (4.2% down) in pre-market, giving back a portion of its recent multi-day rally. * DexCom is facing scrutiny following a voluntary...